Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for rare diseases or, at least, for conditions with severe unmet needs.
However, there is one significant difference between the two. Vertex has a long track record of clinical and regulatory success in its core therapeutic area, which has allowed it to generate growing revenue, profits, and outsized returns for years.
If Sarepta Therapeutics can come close to matching the overall performance of its larger peer over the long run, that would make it an excellent stock to buy today. Does the mid-cap biotech have what it takes? Let's find out.
Source Fool.com
Sarepta Therapeutics Aktie
Unklare Tendenz: Sarepta Therapeutics mit nur wenigen Buy- und Sell-Einschätzungen.
Ein überraschend negatives Potenzial von -2.0% für Sarepta Therapeutics, trotz eines Kursziels von 130 €, das unter 132.65 € liegt.
